| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |